Status:
COMPLETED
Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone
Lead Sponsor:
AstraZeneca
Conditions:
Heart Failure
Ventricular Dysfunction, Left
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose is to study if HF treatment guided by NTproBNP in addition to clinical symptoms and signs is more effective than treatment guided by clinical symptoms and signs alone in patients with HF a...
Eligibility Criteria
Inclusion
- Female/male, over 18 years with previously verified HF with left ventricular systolic dysfunction.
- New York Heart Association(NYHA) class II-IV,
- NTproBNP males\>800 ng/L, females \>1000 ng/L
Exclusion
- Planned CV hospitalisation, stroke or acute myocardial infarction (MI) last 3 months,
- Mitral/aortic stenosis,
- Patients already receiving optimal HF treatment,
- Severe reduction of kidney function
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
252 Patients enrolled
Trial Details
Trial ID
NCT00391846
Start Date
October 1 2006
End Date
January 1 2009
Last Update
June 25 2012
Active Locations (39)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Alvesta, Sweden
2
Research Site
Arvika, Sweden
3
Research Site
Bjuv, Sweden
4
Research Site
Borensberg, Sweden